https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/supported-interventions
It used to be listed as part of the 2024 cohort. You can see it was on the list in the past on the waybackmachine (so no “Mandela effect” here)
Also worth noting that “Trametinib + Rapamycin” was changed to Trametinib only.
Honestly REALLY disappointing if they chose to axe glynac as that looked to be the most promising one. Changing “Trametinib + Rapamycin” to just Trametinib on the other hand could be justified as wanting to see it if extends lifespan on it’s own before testing it with rapa.